Cargando…

Expression of neurofibromin 1 in colorectal cancer and cetuximab resistance

Neurofibromin 1 (NF1) is a tumor suppressor that has been previously reported to regulate RAS-MAPK signaling. The present study investigated the possible relationship between NF1 expression and anti-EGFR antibody (cetuximab) sensitivity in colorectal cancer cell lines. In addition, primary or metast...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tak, Eunyoung, Kim, Minhee, Cho, Youngra, Choi, Sueun, Kim, Jihun, Han, Buhm, Kim, Hyung-Don, Jang, Chloe Soo-Hyun, Kim, Jeong Eun, Hong, Yong Sang, Kim, Sun Young, Kim, Tae Won
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611403/ https://www.ncbi.nlm.nih.gov/pubmed/34779495 http://dx.doi.org/10.3892/or.2021.8226

Ejemplares similares

Dynamic increase of M2 macrophages is associated with disease progression of colorectal cancers following cetuximab-based treatment
por: Kim, Hyung-Don, et al.
Publicado: (2022)

Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer
por: Kim, Dalyong, et al.
Publicado: (2017)

Use of a High-Throughput Genotyping Platform (OncoMap) for RAS Mutational Analysis to Predict Cetuximab Efficacy in Patients with Metastatic Colorectal Cancer
por: Kim, Dalyong, et al.
Publicado: (2017)

Identification of immune-related mechanisms of cetuximab induced skin toxicity in colorectal cancer patients
por: Park, Jin Hyun, et al.
Publicado: (2022)

Clinicogenomic Characteristics and Treatment of Young-Onset Colorectal Cancer Patients Treated With Palliative Therapy in Real-World Practice
por: Jeong, Hyehyun, et al.
Publicado: (2022)

A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab
por: Lee, Sang-Kyu, et al.
Publicado: (2018)

Histopathologic and Molecular Biomarkers of PD-1/PD-L1 Inhibitor Treatment Response among Patients with Microsatellite Instability–High Colon Cancer
por: Hyung, Jaewon, et al.
Publicado: (2022)

Neurofibromin Structure, Functions and Regulation
por: Bergoug, Mohammed, et al.
Publicado: (2020)

Identification of Germinal Neurofibromin Hotspots
por: Lois, Sergio, et al.
Publicado: (2022)

Amphiregulin can predict treatment resistance to palliative first-line cetuximab plus FOLFIRI chemotherapy in patients with RAS wild-type metastatic colorectal cancer
por: Kim, Sang-A, et al.
Publicado: (2021)

Sonic hedgehog pathway activation is associated with cetuximab resistance and EPHB3 receptor induction in colorectal cancer
por: Park, Seong Hye, et al.
Publicado: (2019)

Combination of NTP with cetuximab inhibited invasion/migration of cetuximab-resistant OSCC cells: Involvement of NF-κB signaling
por: Chang, Jae Won, et al.
Publicado: (2015)

Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines
por: Kim, Sujin, et al.
Publicado: (2019)

Reduced expression of neurofibromin in human meningiomas.
por: Sundaram, V., et al.
Publicado: (1997)

Neurofibromin controls macropinocytosis and phagocytosis in Dictyostelium
por: Bloomfield, Gareth, et al.
Publicado: (2015)

Restoring functional neurofibromin by protein transduction
por: Mellert, K., et al.
Publicado: (2018)

Neurofibromin expression by normal salivary glands
por: Luna, Eloá Borges, et al.
Publicado: (2021)

Comprehensive evaluation of the tumor immune microenvironment and its dynamic changes in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy: From the phase II ADORE study
por: Cho, Hyungwoo, et al.
Publicado: (2022)

Structural Insights into the SPRED1-Neurofibromin-KRAS Complex and Disruption of SPRED1-Neurofibromin Interaction by Oncogenic EGFR
por: Yan, Wupeng, et al.
Publicado: (2020)

p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer
por: Kim, Se Hyun, et al.
Publicado: (2016)

Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients
por: Bray, Steven M., et al.
Publicado: (2019)

A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair–Deficient/Microsatellite Instability–High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer
por: Kim, Jwa Hoon, et al.
Publicado: (2020)

Immune Profile of BRAF-Mutated Metastatic Colorectal Tumors with Good Prognosis after Palliative Chemotherapy
por: Kim, Jeong Eun, et al.
Publicado: (2022)

A Phase II Study of Cetuximab (Erbitux®) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer
por: Koo, Dong Hoe, et al.
Publicado: (2007)

Immuno-genomic classification of colorectal cancer organoids reveals cancer cells with intrinsic immunogenic properties associated with patient survival
por: Cho, Eun Jeong, et al.
Publicado: (2021)

Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan
por: Kim, Seung Tae, et al.
Publicado: (2015)

The C-terminal domains of human neurofibromin and its budding yeast homologs Ira1 and Ira2 regulate the metaphase to anaphase transition
por: Luo, Guangming, et al.
Publicado: (2014)

Neurofibromin 1 Is a miRNA Target in Neurons
por: Paschou, Maria, et al.
Publicado: (2012)

Neurofibromin Loss of Function Drives Excessive Grooming in Drosophila
por: King, Lanikea B., et al.
Publicado: (2016)

The therapeutic potential of neurofibromin signaling pathways and binding partners
por: Báez-Flores, Juan, et al.
Publicado: (2023)

Neurofibromin 1 regulates early developmental sleep in Drosophila
por: Durkin, Jaclyn, et al.
Publicado: (2023)

Analysis of Syndecan-2 Methylation in Bowel Lavage Fluid for the Detection of Colorectal Neoplasm
por: Park, Young Sook, et al.
Publicado: (2018)

Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype
por: Kwon, Yujin, et al.
Publicado: (2017)

β-catenin activation down-regulates cell-cell junction-related genes and induces epithelial-to-mesenchymal transition in colorectal cancers
por: Kim, Won Kyu, et al.
Publicado: (2019)

Antibody-Based Targeting of Cell Surface GRP94 Specifically Inhibits Cetuximab-Resistant Colorectal Cancer Growth
por: Jeoung, Mee Hyun, et al.
Publicado: (2019)

CEA dynamics for predicting response after anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer
por: Kang, Sora, et al.
Publicado: (2023)

Patients’ Preferences for Primary Colorectal Cancer Screening: A Survey of the National Colorectal Cancer Screening Program in Korea
por: Cho, Young-Hak, et al.
Publicado: (2017)

The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer
por: Kim, Seung Tae, et al.
Publicado: (2017)

Characterization of biological responses of colorectal cancer cells to anticancer regimens
por: Roh, Seon Ae, et al.
Publicado: (2012)

Genetic Interactions between Neurofibromin and Endothelin Receptor B in Mice
por: Deo, Mugdha, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_s9i1i6khul7a9kscf394kc93ln